to-BBB announced that the Food and Drug Administration (FDA) has granted orphan drug designation for to-BBB’s brain cancer lead product 2B3-101. As a proprietary brain-targeted version of the marketed product Caelyx®/Doxil® (PEG-liposomal doxorubicin), 2B3-101 uses glutathione (GSH) to safely enha more
To use all functions of this page, please activate cookies in your browser.
